TapewireFind a company

person · Reporting owner

Callos Andrew

Disclosed activity across 1 company

Tapewire entity
18477
SEC CIK
0001852129

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
CYTOKINETICS INCCYTK · Entity 3528EVP, Chief Commercial OfficerAugust 31, 2026August 31, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CYTOKINETICS INC

Report date August 31, 2026 · Filed August 31, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect58,555 Ending reported balance After 2026-08-31 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-08-31 · Exercise / conversion · Acquired 10,000 · Balance 68,555

Row 2 · 2026-08-31 · Sale · Disposed 10,000 · Balance 58,555

Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.26 · Expires 2031-03-31Direct0 Reported balance After 2026-08-31 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-08-31 · Exercise / conversion · Disposed 10,000 · Balance 0

F1: Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
January 02, 2026 Filed Jan 2, 2026 23:01 UTC CYTOKINETICS INC CYTK · Entity 3528 Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative 885 $0.00 Strike: $37.63 $0.00
Disclosure

SEC source: 0001061983-26-000001 · form4.xml · derivative · entry 4

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,772

Underlying: Common Stock · 885 shares

Expires 2032-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 02, 2026 Filed Jan 2, 2026 23:01 UTC CYTOKINETICS INC CYTK · Entity 3528 SaleCommon Stock 885 $63.16 $55,896.60
Disclosure

SEC source: 0001061983-26-000001 · form4.xml · nonDerivative · entry 3

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,440

Read SEC document
January 02, 2026 Filed Jan 2, 2026 23:01 UTC CYTOKINETICS INC CYTK · Entity 3528 Exercise / conversionCommon Stock 885 $37.63 $33,302.55
Disclosure

SEC source: 0001061983-26-000001 · form4.xml · nonDerivative · entry 2

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,325

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 02, 2026 Filed Jan 2, 2026 23:01 UTC CYTOKINETICS INC CYTK · Entity 3528 SaleCommon Stock 913 $62.09 $56,688.17
Disclosure

SEC source: 0001061983-26-000001 · form4.xml · nonDerivative · entry 1

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,440

Read SEC document
December 29, 2025 Filed Dec 30, 2025 21:34 UTC CYTOKINETICS INC CYTK · Entity 3528 SaleCommon Stock 1,809 $62.44 $112,953.96
Disclosure

SEC source: 0001061983-25-000057 · form4.xml · nonDerivative · entry 1

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,353

Read SEC document
December 22, 2025 Filed Dec 29, 2025 21:04 UTC CYTOKINETICS INC CYTK · Entity 3528 Tax withholdingCommon Stock 675 $62.72 $42,336.00
Disclosure

SEC source: 0001061983-25-000054 · form4.xml · nonDerivative · entry 3

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,162

F3 · kind: Withholding of shares for tax withholding on vesting of performance shares.

Read SEC document
December 22, 2025 Filed Dec 29, 2025 21:04 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantCommon Stock 1,588 $0.00 $0.00
Disclosure

SEC source: 0001061983-25-000054 · form4.xml · nonDerivative · entry 2

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,837

F2 · kind: Performance shares earned upon achievement of performance goal. Shares remain subject to 1-year vesting requirement.

Read SEC document
December 22, 2025 Filed Dec 29, 2025 21:04 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantCommon Stock 1,589 $0.00 $0.00
Disclosure

SEC source: 0001061983-25-000054 · form4.xml · nonDerivative · entry 1

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,249

F1 · kind: Performance shares earned upon achieving performance goal. Shares vested immediately.

Read SEC document
December 08, 2025 Filed Dec 8, 2025 22:28 UTC CYTOKINETICS INC CYTK · Entity 3528 Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative 1,042 $0.00 Strike: $39.13 $0.00
Disclosure

SEC source: 0001061983-25-000049 · form4.xml · derivative · entry 3

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,403

Underlying: Common Stock · 1,042 shares

Expires 2033-03-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 08, 2025 Filed Dec 8, 2025 22:28 UTC CYTOKINETICS INC CYTK · Entity 3528 SaleCommon Stock 1,042 $65.96 $68,730.32
Disclosure

SEC source: 0001061983-25-000049 · form4.xml · nonDerivative · entry 2

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,660

Read SEC document
December 08, 2025 Filed Dec 8, 2025 22:28 UTC CYTOKINETICS INC CYTK · Entity 3528 Exercise / conversionCommon Stock 1,042 $39.13 $40,773.46
Disclosure

SEC source: 0001061983-25-000049 · form4.xml · nonDerivative · entry 1

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,702

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 05, 2025 Filed Dec 5, 2025 22:35 UTC CYTOKINETICS INC CYTK · Entity 3528 Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative 10,628 $0.00 Strike: $37.63 $0.00
Disclosure

SEC source: 0001061983-25-000048 · form4.xml · derivative · entry 9

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,657

Underlying: Common Stock · 10,628 shares

Expires 2032-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 05, 2025 Filed Dec 5, 2025 22:35 UTC CYTOKINETICS INC CYTK · Entity 3528 Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative 15,858 $0.00 Strike: $37.63 $0.00
Disclosure

SEC source: 0001061983-25-000048 · form4.xml · derivative · entry 8

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,857

Underlying: Common Stock · 15,858 shares

Expires 2032-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 05, 2025 Filed Dec 5, 2025 22:35 UTC CYTOKINETICS INC CYTK · Entity 3528 Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative 11,000 $0.00 Strike: $39.13 $0.00
Disclosure

SEC source: 0001061983-25-000048 · form4.xml · derivative · entry 7

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,445

Underlying: Common Stock · 11,000 shares

Expires 2033-03-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 05, 2025 Filed Dec 5, 2025 22:35 UTC CYTOKINETICS INC CYTK · Entity 3528 Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative 15,000 $0.00 Strike: $23.26 $0.00
Disclosure

SEC source: 0001061983-25-000048 · form4.xml · derivative · entry 6

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 114,000

Underlying: Common Stock · 15,000 shares

Expires 2031-03-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 05, 2025 Filed Dec 5, 2025 22:35 UTC CYTOKINETICS INC CYTK · Entity 3528 SaleCommon Stock 52,486 $65.95 $3,461,451.70
Disclosure

SEC source: 0001061983-25-000048 · form4.xml · nonDerivative · entry 5

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,660

Read SEC document
December 05, 2025 Filed Dec 5, 2025 22:35 UTC CYTOKINETICS INC CYTK · Entity 3528 Exercise / conversionCommon Stock 10,628 $37.63 $399,931.64
Disclosure

SEC source: 0001061983-25-000048 · form4.xml · nonDerivative · entry 4

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,146

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 05, 2025 Filed Dec 5, 2025 22:35 UTC CYTOKINETICS INC CYTK · Entity 3528 Exercise / conversionCommon Stock 15,858 $37.63 $596,736.54
Disclosure

SEC source: 0001061983-25-000048 · form4.xml · nonDerivative · entry 3

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 92,518

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 05, 2025 Filed Dec 5, 2025 22:35 UTC CYTOKINETICS INC CYTK · Entity 3528 Exercise / conversionCommon Stock 11,000 $39.13 $430,430.00
Disclosure

SEC source: 0001061983-25-000048 · form4.xml · nonDerivative · entry 2

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 76,660

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 05, 2025 Filed Dec 5, 2025 22:35 UTC CYTOKINETICS INC CYTK · Entity 3528 Exercise / conversionCommon Stock 15,000 $23.26 $348,900.00
Disclosure

SEC source: 0001061983-25-000048 · form4.xml · nonDerivative · entry 1

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 65,660

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 03, 2025 Filed Dec 5, 2025 21:23 UTC CYTOKINETICS INC CYTK · Entity 3528 Tax withholdingCommon Stock 1,368 $65.02 $88,947.36
Disclosure

SEC source: 0001061983-25-000045 · form4.xml · nonDerivative · entry 1

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,660

F1 · kind: Sell to cover transaction for tax withholding upon vesting of Performance Stock Units granted on March 14, 2024 and earned December 2, 2024.

Read SEC document
June 05, 2025 Filed Jun 5, 2025 20:38 UTC CYTOKINETICS INC CYTK · Entity 3528 SaleCommon Stock 8,659 $32.04 $277,434.36
Disclosure

SEC source: 0001127602-25-016865 · form4.xml · nonDerivative · entry 1

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 52,028

Read SEC document
May 05, 2025 Filed May 5, 2025 22:21 UTC CYTOKINETICS INC CYTK · Entity 3528 SaleCommon Stock 4,002 $36.68 $146,793.36
Disclosure

SEC source: 0001127602-25-013404 · form4.xml · nonDerivative · entry 1

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 60,687

Read SEC document
April 07, 2025 Filed Apr 7, 2025 21:03 UTC CYTOKINETICS INC CYTK · Entity 3528 SaleCommon Stock 2,886 $35.78 $103,261.08
Disclosure

SEC source: 0001127602-25-011767 · form4.xml · nonDerivative · entry 1

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 64,689

Read SEC document
March 17, 2025 Filed Mar 18, 2025 00:23 UTC CYTOKINETICS INC CYTK · Entity 3528 SaleCommon Stock 2,775 $44.38 $123,154.50
Disclosure

SEC source: 0001127602-25-009712 · form4.xml · nonDerivative · entry 1

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,888

F1 · kind: Sell to cover transaction in connection with the vesting of restricted stock units.

Read SEC document
March 17, 2025 Filed Mar 17, 2025 20:33 UTC CYTOKINETICS INC CYTK · Entity 3528 Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative 20,900 $0.00 Strike: $23.26 $0.00
Disclosure

SEC source: 0001127602-25-009691 · form4.xml · derivative · entry 3

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 129,000

Underlying: Common Stock · 20,900 shares

Expires 2031-03-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer.

Read SEC document
March 17, 2025 Filed Mar 17, 2025 20:33 UTC CYTOKINETICS INC CYTK · Entity 3528 SaleCommon Stock 20,900 $45.14 $943,426.00
Disclosure

SEC source: 0001127602-25-009691 · form4.xml · nonDerivative · entry 2

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,663

Read SEC document
March 17, 2025 Filed Mar 17, 2025 20:33 UTC CYTOKINETICS INC CYTK · Entity 3528 Exercise / conversionCommon Stock 20,900 $23.26 $486,134.00
Disclosure

SEC source: 0001127602-25-009691 · form4.xml · nonDerivative · entry 1

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 58,563

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 14, 2025 Filed Mar 15, 2025 00:53 UTC CYTOKINETICS INC CYTK · Entity 3528 Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative 100 $0.00 Strike: $23.26 $0.00
Disclosure

SEC source: 0001127602-25-009556 · form4.xml · derivative · entry 3

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 149,900

Underlying: Common Stock · 100 shares

Expires 2031-03-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer.

Read SEC document
March 14, 2025 Filed Mar 15, 2025 00:53 UTC CYTOKINETICS INC CYTK · Entity 3528 SaleCommon Stock 100 $45.00 $4,500.00
Disclosure

SEC source: 0001127602-25-009556 · form4.xml · nonDerivative · entry 2

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,663

Read SEC document
March 14, 2025 Filed Mar 15, 2025 00:53 UTC CYTOKINETICS INC CYTK · Entity 3528 Exercise / conversionCommon Stock 100 $23.26 $2,326.00
Disclosure

SEC source: 0001127602-25-009556 · form4.xml · nonDerivative · entry 1

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,763

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 14, 2025 Filed Mar 18, 2025 20:20 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantNon-Qualified Stock Option (Right to Buy) · Derivative 47,593 $0.00 Strike: $44.36 $0.00
Disclosure

SEC source: 0001127602-25-009765 · form4.xml · derivative · entry 3

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,593

Underlying: Common Stock · 47,593 shares

Expires 2035-03-13

F3 · kind: Stock options vest in equal monthly installments over 48 months from the date of grant, subject to Mr. Callos's continued employment with the company on the scheduled vesting date.

Read SEC document
March 14, 2025 Filed Mar 18, 2025 20:20 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantIncentive Stock Option (Right to Buy) · Derivative 2,749 $0.00 Strike: $44.36 $0.00
Disclosure

SEC source: 0001127602-25-009765 · form4.xml · derivative · entry 2

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,749

Underlying: Common Stock · 2,749 shares

Expires 2035-03-14

F2 · kind: Stock options vest in equal monthly installments over 48 months from the date of grant, subject to Mr. Callos's continued employment with the company on the scheduled vesting date.

Read SEC document
March 14, 2025 Filed Mar 18, 2025 20:20 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantCommon Stock 32,687 $0.00 $0.00
Disclosure

SEC source: 0001127602-25-009765 · form4.xml · nonDerivative · entry 1

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,350

F1 · kind: Comprised of restricted stock units that convert to shares of common stock on a 1:1 basis upon vesting. 40% of the RSUs will vest on the 1-year anniversary of the date of grant; an additional 40% of the RSUs will vest on the 2-year anniversary of the date of grant; and the final 20% of the RSUs will vest on the 3-year anniversary of the date of grant, in each case subject to Mr. Callos's continued employment with the company on the scheduled vesting date.

Read SEC document
March 13, 2025 Filed Mar 13, 2025 20:30 UTC CYTOKINETICS INC CYTK · Entity 3528 SaleCommon Stock 26,771 $43.62 $1,167,751.02
Disclosure

SEC source: 0001127602-25-009355 · form4.xml · nonDerivative · entry 1

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,663

Read SEC document
March 06, 2025 Filed Mar 8, 2025 01:43 UTC CYTOKINETICS INC CYTK · Entity 3528 SaleCommon Stock 3,341 $43.27 $144,565.07
Disclosure

SEC source: 0001127602-25-008792 · form4.xml · nonDerivative · entry 1

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,434

F1 · kind: Sale to cover transaction in connection with the vesting of restricted stock units.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:37 UTC CYTOKINETICS INC CYTK · Entity 3528 SaleCommon Stock 1,114 $42.88 $47,768.32
Disclosure

SEC source: 0001127602-25-008316 · form4.xml · nonDerivative · entry 1

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,775

F1 · kind: Sale to cover transaction in relation to vesting of restricted stock units.

Read SEC document
December 03, 2024 Filed Dec 5, 2024 21:22 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantCommon Stock 3,177 $0.00 $0.00
Disclosure

SEC source: 0001127602-24-028713 · form4.xml · nonDerivative · entry 3

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,889

F3 · kind: Transaction represents shares of PSUs whose performance condition was satisfied but that remain subject to time-based vesting. These PSUs to vest in full December 3, 2025.

Read SEC document
December 03, 2024 Filed Dec 5, 2024 21:22 UTC CYTOKINETICS INC CYTK · Entity 3528 Tax withholdingCommon Stock 1,351 $51.51 $69,590.01
Disclosure

SEC source: 0001127602-24-028713 · form4.xml · nonDerivative · entry 2

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,712

F2 · kind: Transaction represents withholding of shares to satisfy grantee's tax obligations in connection with vesting PSUs.

Read SEC document
December 03, 2024 Filed Dec 5, 2024 21:22 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantCommon Stock 3,176 $0.00 $0.00
Disclosure

SEC source: 0001127602-24-028713 · form4.xml · nonDerivative · entry 1

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,063

F1 · kind: Transaction represents gross shares of common stock received by grantee upon vesting of Performance Stock Units ("PSUs").

Read SEC document
March 14, 2024 Filed Mar 18, 2024 23:02 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantIncentive Stock Option (Right to Buy) · Derivative 1,224 $0.00 Strike: $63.75 $0.00
Disclosure

SEC source: 0001127602-24-010517 · form4.xml · derivative · entry 3

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,224

Underlying: Common Stock · 1,224 shares

Expires 2034-03-14

F2 · kind: This option shall vest and become exercisable in equal monthly installments over 4 years commencing on April 15, 2024, with the final installment vesting on March 14, 2028.

Read SEC document
March 14, 2024 Filed Mar 18, 2024 23:02 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantNon-Qualified Stock Option (Right to Buy) · Derivative 18,346 $0.00 Strike: $63.75 $0.00
Disclosure

SEC source: 0001127602-24-010517 · form4.xml · derivative · entry 2

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,346

Underlying: Common Stock · 18,346 shares

Expires 2034-03-14

F2 · kind: This option shall vest and become exercisable in equal monthly installments over 4 years commencing on April 15, 2024, with the final installment vesting on March 14, 2028.

Read SEC document
March 14, 2024 Filed Mar 18, 2024 23:02 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantCommon Stock 16,941 $0.00 $0.00
Disclosure

SEC source: 0001127602-24-010517 · form4.xml · nonDerivative · entry 1

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,887

F1 · kind: Award comprised of Restricted Stock Units that will vest over 3-years, with 40% vesting on the 1-year anniversary of the date of grant, an additional 40% vesting on the 2-year anniversary of the date of grant, and the remaining 20% vesting on the 3-year anniversary of the date of grant.

Read SEC document
March 06, 2024 Filed Mar 7, 2024 21:18 UTC CYTOKINETICS INC CYTK · Entity 3528 Tax withholdingCommon Stock 5,103 $66.88 $341,288.64
Disclosure

SEC source: 0001127602-24-009010 · form4.xml · nonDerivative · entry 2

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,946

F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units and does not represent a sale by the reporting person.

Read SEC document
March 04, 2024 Filed Mar 7, 2024 21:18 UTC CYTOKINETICS INC CYTK · Entity 3528 Tax withholdingCommon Stock 2,202 $67.68 $149,031.36
Disclosure

SEC source: 0001127602-24-009010 · form4.xml · nonDerivative · entry 1

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,049

F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units and does not represent a sale by the reporting person.

Read SEC document
March 06, 2023 Filed Mar 7, 2023 21:13 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantNon-Qualified Stock Option (Right to Buy) · Derivative 47,445 $0.00 Strike: $39.13 $0.00
Disclosure

SEC source: 0001127602-23-009282 · form4.xml · derivative · entry 3

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,445

Underlying: Common Stock · 47,445 shares

Expires 2033-03-06

F2 · kind: This option shall vest and become exercisable in equal monthly installments over 4 years commencing on April 6, 2023, with the final installment vesting on April 6, 2027.

Read SEC document
March 06, 2023 Filed Mar 7, 2023 21:13 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantIncentive Stock Option (Right to Buy) · Derivative 2,555 $0.00 Strike: $39.13 $0.00
Disclosure

SEC source: 0001127602-23-009282 · form4.xml · derivative · entry 2

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,555

Underlying: Common Stock · 2,555 shares

Expires 2033-03-06

F2 · kind: This option shall vest and become exercisable in equal monthly installments over 4 years commencing on April 6, 2023, with the final installment vesting on April 6, 2027.

Read SEC document
March 06, 2023 Filed Mar 7, 2023 21:13 UTC CYTOKINETICS INC CYTK · Entity 3528 GrantCommon Stock 30,000 $0.00 $0.00
Disclosure

SEC source: 0001127602-23-009282 · form4.xml · nonDerivative · entry 1

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,683

F1 · kind: Award comprised of Restricted Stock Units that will vest over 3-years, with 40% vesting on the 1-year anniversary of the date of grant, an additional 40% vesting on the 2-year anniversary of the date of grant, and the remaining 20% vesting on the 3-year anniversary of the date of grant.

Read SEC document
March 02, 2023 Filed Mar 3, 2023 23:09 UTC CYTOKINETICS INC CYTK · Entity 3528 Tax withholdingCommon Stock 2,202 $39.60 $87,199.20
Disclosure

SEC source: 0001127602-23-008853 · form4.xml · nonDerivative · entry 1

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,683

F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on March 2, 2023 and does not represent a sale by the reporting person.

Read SEC document
February 16, 2023 Filed Feb 17, 2023 22:43 UTC CYTOKINETICS INC CYTK · Entity 3528 Tax withholdingCommon Stock 969 $44.13 $42,761.97
Disclosure

SEC source: 0001127602-23-005915 · form4.xml · nonDerivative · entry 1

Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,885

F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on February 16, 2023 and does not represent a sale by the reporting person.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.